bluuebunny/crossref_metadata_2025_split huggingface dataset:
Chicken liver and eggshell crackers as a safe and affordable animal source food for overcoming micronutrient deficits during pregnancy and lactation in Indonesia: a double-blind, randomised placebo-controlled trial (SISTIK Growth Study)
Authors: Diana Aly , Rahmannia Sofa , Suhadi Yenni Zuhairini , Luftimas Dimas Erlangga , Rizqi Haidar , Purnamasari Afini Dwi , Jihadillah Ayunda , Ansari Mohammad Brachim , Haq Dearly Ayu Zahrotun , Pratiwi Aisyah Nur , Scott Samuel , Hampel Daniela , Allen Lindsay H , Haszard Jillian J , Houghton Lisa A , Gibson Rosalind S , Fahmida Umi 
Published: June 2022

Background: Indonesia ranks fifth in terms of the number of stunted children and there has been little change in the stunting prevalence in the last decade. In earlier observational studies conducted in 2014-2015, we identified several key underlying problems with the potential to impact stunting in Sumedang district, West Java, Indonesia. Deficits in intakes of growth-limiting micronutrients were observed, most notably calcium, iron, zinc, and vitamin A, emphasizing the need for a food-based intervention to overcome these micronutrient deficits in the diets of mothers and their infants. Methods: A double-blind placebo-controlled cluster randomised trial comparing the effect of daily consumption of 75 grams of locally produced micronutrient-enriched crackers (MEC) (intervention group) compared to placebo crackers (control group) by mothers at two-time intervals: (i) from the 8-14 weeks of pregnancy to delivery (i.e., 28-34 weeks of consumption of MEC) on birth length, and (ii) from the 8-14 weeks of pregnancy to 5 months post-partum on attained linear growth and linear growth velocity of breast-fed infants. A total of 324 pregnant women from 28 clusters (villages) located in 3 sub-districts in Sumedang district, West Java, Indonesia, will be randomly assigned to either intervention (n=14 villages) or control (n=14 villages). Discussion: This will be the first study in Indonesia to use crackers based on powdered eggshells and chicken liver, in a form which is acceptable, safe, and has a long shelf life. If daily consumption of MEC for 6 months during pregnancy can enhance birth length, or their continued daily consumption for 5 months postpartum improves both attained and incremental linear growth at 5 months of age, then scaling-up in Indonesia may be considered. Trial Registration: https://clinicaltrials.gov/ct2/show/NCT04564222; 25th September 2020
Measuring Founding Strategy
Authors: Guzman Jorge , Li Aishen 
Published: June 2022

We introduce a novel approach to measure the founding strategic differentiation of startups and its relationship to follow-on performance. We use natural language processing and historical websites to estimate the similarity between the founding website of an individual startup, the historical website of public firms at the startup’s founding year, and the founding website of other startups founded in the same year. We propose that distance in the value proposition stated in these websites represents differentiation in the market. Startup differentiation is estimated as the average text-based distance from the five closest incumbents (public firms). We implement this approach using a large sample of startups from Crunchbase. Our measure predicts a meaningful increase in early-stage financing and equity outcomes, unconditionally and controlling for cohort and industry fixed effects. The positive benefits of equity outcomes only evidence themselves after year 6 of age, suggesting more differentiated firms may take longer to prove themselves. Using out-of-sample tests, we also demonstrate that our measure is economically important, predicting 30% of the total variation in the receipt of early-stage financing and 20% of variation in equity outcomes. Public datasets of our differentiation score and scraped website data are provided, together with open-source code to replicate our approach in other settings. This paper was accepted by Joshua Gans, business strategy. Supplemental Material: The data files and online appendices are available at https://doi.org/10.1287/mnsc.2022.4369 .
Advanced airway management and drug-assisted intubation skills in an advanced critical care practitioner team
Authors: Denton Gavin , Green Lindsay , Palmera Marion , Jones Anita , Quinton Sarah , Simmons Andrew , Choyce Andrew , Higgins Daniel , Arora Nitin 
Published: June 2022

Introduction: Airway management, including endotracheal intubation, is one of the cornerstones of care of critically ill patients. Internationally, health professionals from varying backgrounds deliver endotracheal intubation as part of their critical care role. This article considers the development of airway management skills within a single advanced critical care practitioner (ACCP) team and uses case series data to analyse the safety profile in performing this aspect of critical care. Skills were acquired during and after the ACCP training pathway. A combination of theoretical teaching, theatre experience, simulation and work-based practice was used. Case series data of all critical care intubations by ACCPs were collected. Audit results: Data collection identified 675 intubations carried out by ACCPs, 589 of those being supervised, non-cardiac arrest intubations requiring drugs. First pass success was achieved in 89.6% of cases. A second intubator was required in 4.3% of cases. Some form of complication was experienced by 42.3% of patients; however, the threshold for complications was set at a low level. Conclusions: This ACCP service developed a process to acquire advanced airway management skills including endotracheal intubation. Under medical supervision, ACCPs delivered advanced airway management achieving a first pass success rate of 89.6%, which compares favourably with both international and national success rates. Although complications were experienced in 48.3% of patients, when similar complication cut-offs are compared with published data, ACCPs also matched favourably.
Cost-effectiveness of Debrichem in managing hard-to-heal venous leg ulcers in the UK
Authors: Guest Julian F , Deanesi Valter , Segalla Arrigo 
Published: June 2022

Objective: To estimate whether the topical debriding agent, Debrichem, could potentially afford the UK's National Health Service (NHS) a cost-effective intervention for the management of hard-to-heal venous leg ulcers (VLUs). Method: A Markov model was constructed depicting the management of hard-to-heal VLUs with Debrichem plus standard care (SC) or SC alone over a period of 12 months. The model was populated with inputs from an indirect comparison of two propensity score-matched cohorts. The model estimated the cost-effectiveness of the two interventions in terms of the incremental cost per quality–adjusted life year (QALY) gained at 2019/20 prices. Results: Addition of Debrichem to a SC protocol to treat hard-to-heal VLUs was found to increase the probability of healing by 75% (from 0.35 to 0.61) by 12 months, and to increase health-related quality of life over 12 months from 0.74 to 0.84 QALYs per patient. The 12-month cost of treatment with Debrichem plus SC (£3128 per patient) instead of SC alone (£7195 per patient) has the potential to reduce the total NHS cost of wound management by up to 57%. Hence, Debrichem was estimated to improve health outcomes for less cost. Sensitivity analysis showed that Debrichem plus SC remained a cost-effective (dominant) treatment with plausible variations in costs and effectiveness. Conclusion: Within the limitations of the study, the addition of Debrichem to a SC protocol potentially affords a cost-effective treatment to the NHS for managing hard-to-heal VLUs.
Hypericum and neem oil for dehisced post-surgical wounds: a randomised, controlled, single-blinded phase III study
Authors: Arena Raimondo , Strazzeri Maria Grazia , Bianchi Tommaso , Peghetti Angela , Merli Yuri , Abbenante Diego , Olivari Diletta 
Published: June 2022

Objective: To evaluate the clinical efficacy of a hypericum and neem oil dressing, Primary Wound Dressing [ONE] (1PWD) (Kerecis AG, Switzerland), in a patient population with dehiscence of surgical wounds with critical colonisation/infection. Efficacy was defined as resolution of inflammatory/infective symptoms. Method: A randomised, controlled, single-blinded, parallel-arms phase III study was conducted comparing the experimental medication to silver-based dressings. All patients were evaluated at enrolment, on days 7, 14, 21 and 28. Improvement of inflammatory/infective symptoms was measured by detecting seven items of the Bates–Jensen Wound Assessment Tool (BWAT). Pain was assessed using the Numeric Rating Scale (NRS). Results: The study enrolled 99 patients. Follow-up was completed in 49 patients in the experimental group and 48 patients in the control group. Overall BWAT evaluation demonstrated similar outcomes between the groups: t=0.23, p-value=0.81, 95% confidence interval (CI): –13.3–10.8. Furthermore, when evaluating the seven items of the BWAT relating to inflammatory signs, there was not a significant difference between the groups: t=0.38, p=0.35, 95% CI: –2.8–2.7. However, when an analysis using the NRS pain scale was performed, a statistically significant pain reduction was demonstrated in favour of the experimental group: t=7.8, p<0.0001, 95% CI: 2.918–4.8819. Conclusion: This randomised controlled trial confirmed the efficacy of 1PWD, an investigational product, in the management of surgical dehiscence with critical colonisation or infection, with the added benefit of significant pain reduction when compared with a silver-based dressing.
Systematic literature review and meta-analysis on use of Thrombopoietic agents for chemotherapy-induced thrombocytopenia
Authors: Soff Gerald A. , Ray-Coquard Isabelle , Rivera Luis J. Marfil , Fryzek Jon , Mullins Megan , Bylsma Lauren C. , Park Joseph K. 
Published: June 2022

BackgroundCurrently, there are no approved options to prevent or treat chemotherapy-induced thrombocytopenia (CIT). We performed a systematic literature review and meta-analysis on use of thrombopoietic agents for CIT.Patients and methodsWe searched Cochrane Central Register of Controlled Trials, Cochrane Database of Systematic Reviews, PubMed, EMBASE, ClinicalTrials.gov, and health technology assessments from January 1995 to March 2021 for studies evaluating thrombopoietic agents for CIT, including recombinant human thrombopoietin (rhTPO), megakaryocyte growth and development factor (MGDF), romiplostim, and eltrombopag. Random effects meta-analyses were conducted for efficacy and safety endpoints.ResultsWe screened 1503 titles/abstracts, assessed 138 articles, and abstracted data from 39 publications (14 recombinant human thrombopoietin, 7 megakaryocyte growth and development factor, 9 romiplostim, 8 eltrombopag, and 1 romiplostim/eltrombopag). Random effects meta-analyses of data from multiple studies comparing thrombopoietic agents versus control (comparator, placebo, or no treatment) showed that thrombopoietic agents did not significantly improve chemotherapy dose delays and/or reductions (21.1% vs 40.4%,P= 0.364), grade 3/4 thrombocytopenia (39.3% vs 34.8%;P= 0.789), platelet transfusions (16.7% vs 31.7%,P= 0.111), grade ≥ 2 bleeding (6.7% vs 16.5%;P= 0.250), or thrombosis (7.6% vs 12.5%;P= 0.131). However, among individual studies comparing thrombopoietic agents with placebo or no treatment, thrombopoietic agents positively improved outcomes in some studies, including significantly increasing mean peak platelet counts (186 x 109/L with rhTPO vs 122 x 109/L with no treatment;P< 0.05) in one study and significantly increasing platelet count at nadir (56 x 109/L with rhTPO vs 28 x 109/L with not treatment;P< 0.05) in another study. Safety findings included thrombosis (n= 23 studies) and bleeding (n= 11), with no evidence of increased thrombosis risk with thrombopoietic agents.ConclusionOur analyses generate the hypothesis that thrombopoietic agents may benefit patients with CIT. Further studies with well-characterized bleeding and platelet thresholds are warranted to explore the possible benefits of thrombopoietic agents for CIT.
Spatiotemporal analysis of cutaneous leishmaniasis in Palestine and foresight study by projections modelling until 2060 based on climate change prediction
Authors: Amro Ahmad , Moskalenko Olga , Hamarsheh Omar , Frohme Marcus 
Published: June 2022

Background
Cutaneous leishmaniasis (CL) is a vector-borne parasitic diseases of public health importance that is prevalent in the West Bank but not in the Gaza Strip. The disease caused by parasitic protozoans from the genus Leishmania and it is transmitted by infected phlebotomine sand flies. The aim of our study is to investigate the eco-epidemiological parameters and spatiotemporal projections of CL in Palestine over a 30-years period from 1990 through 2020 and to explore future projections until 2060.

Methodology/Principal findings
This long-term descriptive epidemiological study includes investigation of demographic characteristics of reported patients by the Palestinian Ministry of Health (PMoH). Moreover, we explored spatiotemporal distribution of CL including future projection based on climate change scenarios. The number of CL patients reported during this period was 5855 cases, and the average annual incidence rate (AAIR) was 18.5 cases/105 population. The male to female ratio was 1.25:1. Patients-age ranged from 2 months to 89 years (mean = 22.5, std 18.67, and the median was 18 years). More than 65% of the cases came from three governates in the West Bank; Jenin 29% (1617 cases), Jericho 25% (1403), and Tubas 12% (658) with no cases reported in the Gaza Strip. Seasonal occurrence of CL starts to increase in December and peaked during March and April of the following year. Current distribution of CL indicate that Jericho, Tubas, Jenin and Nablus have the most suitable climatic settings for the sandfly vectors. Future projections until 2060 suggest an increasing incidence from northwest of Jenin down to the southwest of Ramallah, disappearance of the foci in Jericho and Tubas throughout the Jordan Vally, and possible emergence of new foci in Gaza Strip.

Conclusions/Significance
The future projection of CL in Palestine until 2060 show a tendency of increasing incidence in the north western parts of the West Bank, disappearance from Jericho and Tubas throughout the Jordan Vally, and emergence of new CL endemic foci in the Gaza Strip. These results should be considered to implement effective control and surveillance systems to counteract spatial expansion of CL vectors.
A systematic review of substance use and substance use disorder research in Kenya
Authors: Jaguga Florence , Kiburi Sarah Kanana , Temet Eunice , Barasa Julius , Karanja Serah , Kinyua Lizz , Kwobah Edith Kamaru 
Published: June 2022

Objectives
The burden of substance use in Kenya is significant. The objective of this study was to systematically summarize existing literature on substance use in Kenya, identify research gaps, and provide directions for future research.

Methods
This systematic review was conducted in line with the PRISMA guidelines. We conducted a search of 5 bibliographic databases (PubMed, PsychINFO, Web of Science, Cumulative Index of Nursing and Allied Professionals (CINAHL) and Cochrane Library) from inception until 20 August 2020. In addition, we searched all the volumes of the official journal of the National Authority for the Campaign Against Alcohol & Drug Abuse (the African Journal of Alcohol and Drug Abuse). The results of eligible studies have been summarized descriptively and organized by three broad categories including: studies evaluating the epidemiology of substance use, studies evaluating interventions and programs, and qualitative studies exploring various themes on substance use other than interventions. The quality of the included studies was assessed with the Quality Assessment Tool for Studies with Diverse Designs.

Results
Of the 185 studies that were eligible for inclusion, 144 investigated the epidemiology of substance use, 23 qualitatively explored various substance use related themes, and 18 evaluated substance use interventions and programs. Key evidence gaps emerged. Few studies had explored the epidemiology of hallucinogen, prescription medication, ecstasy, injecting drug use, and emerging substance use. Vulnerable populations such as pregnant women, and persons with physical disability had been under-represented within the epidemiological and qualitative work. No intervention study had been conducted among children and adolescents. Most interventions had focused on alcohol to the exclusion of other prevalent substances such as tobacco and cannabis. Little had been done to evaluate digital and population-level interventions.

Conclusion
The results of this systematic review provide important directions for future substance use research in Kenya.

Systematic review registration
PROSPERO: CRD42020203717.
Fecal microbiota in congenital chloride diarrhea and inflammatory bowel disease
Authors: Wedenoja Satu , Saarikivi Aki , Mälkönen Jani , Leskinen Saara , Lehto Markku , Adeshara Krishna , Tuokkola Jetta , Nikkonen Anne , Merras-Salmio Laura , Höyhtyä Miikka , Hörkkö Sohvi , Haaramo Anu , Salonen Anne , de Vos Willem M. , Korpela Katri , Kolho Kaija-Leena 
Published: June 2022

Background and aims
Subjects with congenital chloride diarrhea (CLD; a defect in solute carrier family 26 member 3 (SLC26A3)) are prone to inflammatory bowel disease (IBD). We investigated fecal microbiota in CLD and CLD-associated IBD. We also tested whether microbiota is modulated by supplementation with the short-chain fatty acid butyrate.

Subjects and methods
We recruited 30 patients with CLD for an observational 3-week follow-up study. Thereafter, 16 consented to oral butyrate substitution for a 3-week observational period. Fecal samples, collected once a week, were assayed for calprotectin and potential markers of inflammation, and studied by 16S ribosomal ribonucleic acid (rRNA) gene amplicon sequencing and compared to that of 19 healthy controls and 43 controls with Crohn’s disease. Data on intestinal symptoms, diet and quality of life were collected.

Results
Patients with CLD had increased abundances of Proteobacteria, Veillonella, and Prevotella, and lower abundances of normally dominant taxa Ruminococcaceae and Lachnospiraceae when compared with healthy controls and Crohn´s disease. No major differences in fecal microbiota were found between CLD and CLD-associated IBD (including two with yet untreated IBD). Butyrate was poorly tolerated and showed no major effects on fecal microbiota or biomarkers in CLD.

Conclusions
Fecal microbiota in CLD is different from that of healthy subjects or Crohn´s disease. Unexpectedly, no changes in the microbiota or fecal markers characterized CLD-associated IBD, an entity with high frequency among patients with CLD.
Identification of volatile compounds and antioxidant, antibacterial, and antifungal properties against drug-resistant microbes of essential oils from the leaves of Mentha rotundifolia var. apodysa Briq. (Lamiaceae)
Authors: Salamatullah Ahmad Mohammad 
Published: June 2022

Abstract
The present research work investigated antioxidant, antibacterial, and antifungal properties of essential oils from the leaves of Mentha rotundifolia var. apodysa Briq. (EOR). Hydro-distillation was used to extract EOR before being subjected to the chemical characterization by the use of GC/MS. Antioxidant activity was assessed by the use of three bioassays namely 1,1-diphenyl-2-picrylhydrazyl (DPPH), ferric reducing antioxidant power (FRAP), and total antioxidant capacity (TAC). Antimicrobial potency was tested against gram-negative and gram-positive bacteria namely Staphylococcus aureus, Streptococcus pneumoniae, Escherichia coli, Acinetobacter baumannii, and Klebsiella pneumonia, while antifungal activity was tested against Aspergillus niger, Candida albicans, Aspergillus flavus, and Fusarium oxysporum. EOR yield was determined to be 1.31%, with 20 compounds wherein Menthol (31.28%) and Isomenthol (14.28%) constituted the greatest amount. Regarding antioxidant activity, EOR exhibited potent antioxidant power: DPPH (IC50 value of 0.36 ± 0.03 mg/mL), FRAP (EC50 value of 0.35 ± 0.03 mg/mL), and TAC (697.45 ± 1.07 mg EAA/g). Antibacterial activity results showed that EOR had broad antibacterial activity on the tested strains. Eventually, EOR resulted in the greatest inhibition zone diameters vs S. aureus (18.20 ± 0.41 mm) followed by E. coli (17.02 ± 0.5 mm). Antifungal activity results showed that EOR exhibited potent antifungal activity and resulted in the greatest inhibition zone diameters up to 51.32 ± 1.32 mm against Aspergillus flavus, and 34.51 ± 1.07 mm against Aspergillus niger.
Plasmonic and bi-piezoelectric enhanced photocatalysis using PVDF/ZnO/Au nanobrush
Authors: Zhao Xiaofei , Li Zhen , Yu Jing , Li Chonghui , Xu Shicai , Li Fengrui , Zhang Chentao , Man Baoyuan , Zhang Chao 
Published: June 2022

Abstract
The photocatalytic degradation, as an environmental-friendly technology, has great significance for cost-effective and efficient catalysis processes, wherein piezo-photocatalysis can significantly increase the catalytic degradation rate using both solar and mechanical energy. Here, a ternary heterostructure PVDF/ZnO/Au (PZA) nanobrush photocatalyst with high piezo-photocatalytic efficiency was presented via low-temperature hydrothermal and chemical reduction methods. Under both solar and mechanical energy, the current response and degradation rate of the as-synthesized PZA nanobrush all increase significantly compared with that under solar alone and under mechanical energy alone, and the excellent recyclability is investigated. It is found that the PZA nanobrush with ultrasonic-assisted piezo-photocatalysis completely degrade MO of 20 mg/L in 60 min, which exhibits greater enhancement of photocatalytic activity than with stirring-assisted piezo-photocatalysis due to higher power. The high piezo-photocatalytic activity of PZA nanobrush is attributed to the surface plasmon resonance (SPR) coupling of Au and built-in electric field originating from the ZnO and PVDF, which can increase the absorption of visible light, promote the charge transfer and separation of photogenerated electrons/holes. This work introduces the SPR and bipiezotronic effect to improve plasmonic photocatalysis with PZA heterostructures, which offers a new solution in green technologies to design high-performance catalysts for the environmental remediation.
Crystal structure of chlorido-(η
6-toluene)(2,2′-bipyridine-κ2
N,N′)ruthenium(II) hexafluorophosphate, C17H16ClN2RuPF6
Authors: Gichumbi Joel M. , Zamisa Sizwe J. , Friedrich Holger B. 
Published: June 2022

Abstract
C17H16ClN2RuPF6, monoclinic, P21/c (no. 14), a = 14.4426(9) Å, b = 8.3311(5) Å, c = 16.413(1) Å, β = 109.2690°, V = 1864.2(2) Å3, Z = 4, R

gt
(F) = 0.0309, wR

ref
(F
2) = 0.0697, T = 173 K.